300639 Guangdong Hybribio Biotech
- 5.24
- -0.12-2.24%
Guangdong Hybribio Biotech News
Guangdong Hybribio Biotech (300639.SZ): The company and its subsidiaries have been granted 2 invention patent authorizations.
On September 2, Guangdong Hybribio Biotech (300639.SZ) announced that the company and its subsidiaries obtained a total of 2 patents in August 2024. The patent names are respectively a method for predicting mitochondrial diseases and a system for predicting mitochondrial diseases, and a sliding compression reaction chamber mechanism.
Capbio: 2024 Semi-Annual Report
Capbio: 2024 Semi-Annual Report Summary
guangdong hybribio biotech (300639.SZ): The net loss for the first half of the year was 76.9292 million yuan.
Guangdong Hybribio Biotech (300639.SZ) released its semi-annual report for 2024 on August 28th, with a reported revenue of 0.409 billion yuan for the reporting period, a decrease of 32.60% year-on-year. The net loss attributable to the shareholders of the listed company was 76.9292 million yuan. The net loss attributable to the shareholders of the listed company, excluding non-recurring gains and losses, was 85.6463 million yuan. The basic loss per share was 0.1195 yuan.
guangdong hybribio biotech (300639.SZ) released its performance for the first half of the year, with a loss of 76.9292 million yuan.
Guangdong Hybribio Biotech (300639.SZ) released its 2024 interim report, with revenue of 0.409 billion...
There is a risk of diffusion! WHO has launched a global strategic preparedness, and monkeypox concept stocks have surged in response.
New variant appears.
Guangdong Hybribio Biotech (300639.SZ): There is currently no business revenue related to smallpox.
Guangdong Hybribio Biotech (300639.SZ) stated on the investor interactive platform on August 21 that the company independently developed Monkeypox Virus nucleic acid detection kit (Fluorescent PCR method) (English name: Monkeypox Virus Real-time PCR Kit) has obtained CE certification, but has not yet obtained domestic medical instruments registration certificate, and has not yet generated revenue from Monkeypox-related business. The company will continue to monitor the progress of Monkeypox-related matters and market demand.
Guangdong Hybribio Biotech Co.,Ltd.'s (SZSE:300639) Price Is Right But Growth Is Lacking After Shares Rocket 36%
As of August 9, 2024, the total number of shareholders for Guangdong Hybribio Biotech (300639.SZ) is 34,097.
Guangdong Hybribio Biotech (300639.SZ) stated on the investor interaction platform on August 13th that as of August 9th, 2024, the total number of shareholders in the company was 34,097.
Guangdong Hybribio Biotech (300639.SZ): Its medical laboratory has the ability to test for monkeypox virus.
On August 13th, Guandong Hybribio Biotech (300639.SZ) stated on its investor relations platform that the company's medical laboratory has the ability to test for monkeypox virus. The company has independently developed a Monkeypox Virus Real-time PCR Kit (fluorescence PCR method) and has obtained CE certification. However, the product has not yet obtained a domestic medical instrument registration certificate. The invention patents related to monkeypox virus include "A kind of monkeypox virus pseudovirus particle and its preparation method" and "A method for simultaneously detecting and identifying monkeypox virus type I, ..."
Is Guangdong Hybribio BiotechLtd (SZSE:300639) Using Debt In A Risky Way?
Guangdong Hybribio Biotech (300639.SZ): has repurchased 0.39% of its shares.
Guangdong Hybribio Biotech (300639.SZ) announced on July 31 that as of July 31, 2024, the company has cumulatively repurchased 2,505,100 shares, accounting for 0.39% of the current total share capital of the company (excluding the shares in the company's repurchase special securities account); the highest fill price for repurchase is RMB 4.81/share, and the lowest fill price is RMB 4.37/share; the total amount of funds paid is RMB 11,347,431.03 yuan (including transaction costs). This share repurchase program complies with relevant laws and regulations and the company's share repurchase plan.
Guangdong Hybribio Biotech (300639.SZ): In July, the company and its subsidiaries received a total of 3 authorized invention patents.
On July 31st, Gelonhui reported that Guangdong Hybribio Biotech (300639.SZ), along with its subsidiaries, obtained a total of three authorized invention patents in July 2024. The patents include a microfluidic chip for live cell sorting, a primer and probe combination for detecting 16 pathogenic mutations of the SLC22A5 gene, and a set of primers and reagents based on nucleic acid mass spectrometry for simultaneous detection of folate and nutrient metabolism gene SNP sites in a single tube.
Guangdong Hybribio Biotech (300639.SZ): Its subsidiary third-party medical laboratory has relevant testing technology reserves and can provide related testing services for the disease.
Guangdong Hybribio Biotech (300639.SZ) stated on the investor interaction platform on July 18 that its third-party medical laboratory has the relevant testing technology reserve and can provide related testing services for the disease.
Guangdong Hybribio Biotech Obtains License for Clinical Laboratory Instruments
Guangdong Hybribio Biotech (300639.SZ): As of June 28th, the total number of shareholders in the company was 33,841.
Guangdong Hybribio Biotech (300639.SZ) stated on the investor interaction platform on July 8th that as of June 28, 2024, the total number of company shareholders is 33,841.
Guangdong Hybribio Biotech (300639.SZ): Repurchased 0.10% of shares in total.
Guangdong Hybribio Biotech (300639.SZ) announced that as of June 30, 2024, the company has repurchased 655,200 shares, accounting for 0.10% of the company's current total share capital (excluding shares in the company's repurchase special securities account). The highest fill price for repurchases was RMB 4.63/share, and the lowest fill price was RMB 4.58/share. The total amount paid was RMB 3,020,811.82 (including transaction costs). This repurchase of shares complies with relevant laws, regulations, and the company's share buyback program.
Guangdong Hybribio Biotech (300639.SZ): The first buyback of 655,200 shares involves 3.0204 million yuan.
On June 28th, Guangdong Hybribio Biotech (stock code 300639.SZ) announced that on June 28th, 2024, the company repurchased its own shares for the first time through centralized bidding trading using the share buyback special securities account. The repurchased quantity was 655,200 shares, accounting for 0.10% of the company's current total share capital (excluding the shares in the company's share buyback special securities account); the highest fill price for the repurchase was RMB 4.58/share, and the lowest fill price was RMB 4.63/share. The total amount of funds paid was RMB 3,020,359.18 (excluding transaction fees).
Guangdong Hybribio Biotech (300639.SZ): plans to spend 30-60 million yuan to repurchase shares.
Guangdong Hybribio Biotech (300639.SZ) announced on June 27th that the company plans to repurchase some of its shares through centralized bidding with its own funds. The company plans to use its own funds of no less than RMB 30 million (inclusive) and no more than RMB 60 million (inclusive) for the repurchase. The repurchase price of shares shall not exceed RMB 7.20 per share (inclusive). The deadline for the implementation of the share repurchase shall not exceed 3 months from the date when the board of directors approves this share repurchase plan.
Guangdong Hybribio Biotech (300639.SZ): Currently there are no other risk warning triggers.
On June 11th, Gelunhui reported that Guangdong Hybribio Biotech (300639.SZ) stated on the investor interaction platform that there is currently no situation triggering other risk warnings according to relevant regulations of the Shenzhen Stock Exchange. In the first quarter of 2024, due to large expenditures related to artificial welfare, depreciation and amortization, leasing, and other expenses in the medical laboratory business, the company's laboratory inspection business sector incurred an overall loss, resulting in a loss in the company's consolidated financial statements. To reverse this situation, the company continues to carry out cost reduction and efficiency improvement work, on one hand, increasing market expansion efforts to improve market share, and on the other hand, strengthening internal management, reducing expenses, and improving laboratory efficiency.
Analysis
Price Target
No Data
